40 results about "Cell Surface Antigens" patented technology

The application discloses a detection method of cell surface antigens and application thereof, and relates to the detection field. The detection method of cell surface antigens comprises the following steps: mixing liposome-treated cells to be detected with capture microspheres and fluorescent microspheres, detecting the fluorescence intensity, and analyzing the expression of cell surface antigens. The surface of the capture microspheres is coated with a first antibody against a specific antigen on the surface of target cells. The surface of the fluorescent microspheres is coated with a second antibody against a target antigen on the surface of target cells. The detection method has low cost and can be used for directly quantitatively and qualitatively analyzing the expression of surface antigens of specific types of cells.

The present invention relates to agents and methods for targeted delivery of a payload to a cell. The payload comprises various molecules, such as therapeutic or diagnostic agents, in particular toxins, immunomodulators or radiodiagnostic agents. In some embodiments, the invention relates to providing a subject with a compound comprising a payload moiety and at least two tags (tag conjugates) and a compound (docking compound) that binds to the tags of the tag conjugates and a target antigen (e.g., a cell surface antigen on a target cell).

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

The present disclosure provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The present invention relates to polypeptides comprising a membrane surface domain and uses thereof. In particular, the present invention provides an engineered polypeptide comprising a membrane surface domain comprising an extracellular domain of a B cell surface antigen or a variant thereof.

The invention discloses a tri-specific antigen binding protein, and relates to a tri-specific antibody specifically binding two tumor antigens GPRC5D and BCMA and a T cell surface antigen CD3, a pharmaceutical composition containing the tri-specific antibody, a preparation method and application.

The present disclosure provides a therapeutic method of treating cancer metastasis by inducing clearance of EVs using a binding agent specific to an EV protein. The method utilizes one or more binding agents specific to EV proteins, where the EV proteins are selected from prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4); CD13 (aminopeptidase N); MME (neprilysin), ENPP1 (ectonucleotide pyrophosphatase / phosphodiesterase family member 1); and NRP1 (neuropilin-1). Further provided herein includes a pharmaceutical composition for the treatment of cancer metastasis.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

Compositions and methods are provided that enhance CAR T-cell therapy by providing an oncolytic virus engineered to direct expression and secretion of a multivalent adapter protein. The multivalent adapter protein targets both a broadly tumor-associated cell surface antigen and an antigen binding domain of a CAR T-cell.

Targeted antineoplastic immunotherapies have achieved remarkable clinical outcomes. However, resistance to these therapies due to target absence or antigen shedding limits their efficacy and excludes tumours from candidacy. The present application discloses new therapeutic agents and methods based on the delivery of cell-surface antigens of interest to tumors using cancer-specific delivery vehicles such as oncolytic viruses to render the tumors sensitive to immunotherapies targeting the cell-surface antigens, including currently approved antibodies, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cells. These therapeutic agents and methods are useful for the treatment of cancers, including cancers not expressing targetable tumor antigens and / or resistant to current immunotherapies.

The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

The present disclosure relates generally to binding agents, such as antibodies and antigen binding fragments thereof, capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents capable of targeting tumor cells expressing TROP2 and their use for the treatment of cancer. A single domain antibody that specifically binds to an amino acid residue of the extracellular domain of TROP2 is provided.

The present invention relates to multispecific binding proteins comprising binding domains with dual-binding specificity for at least one disease-associated antigen, suitably tumor-associated antigen and an immune cell surface antigen. Said binding domains with dual-binding specificity bind to the two targets in a mutually exclusive way, thereby functioning as a molecular switch, such as, e.g., a switch to control activation or deactivation of a therapeutic agent. Said binding proteins are formatted as T cell engagers to optionally comprise a binding domain with co-stimulatory activity, such as CD2. Said binding domains are preferably ankyrin repeat domains, e.g. designed ankyrin repeat domains (DARPins). The invention further relates to nucleic acids, pharmaceutical compositions, recombinant expression vectors and host cells, and the use of such proteins, nucleic acids or pharmaceutical compositions in methods for treating diseases, such as cancer.

The invention relates to the field of bioengineering, in particular to a preparation method of B lymphocytes. The invention provides a preparation method of B lymphocytes. The preparation method comprises the following steps: S1, obtaining a single-cell suspension; s2, performing density gradient centrifugation on the single-cell suspension to obtain interface layer cells rich in mononuclear cells; s3, carrying out T cell lysis on the interface layer cells by adopting a specific antibody and a specific complement of an anti-T cell surface antigen, centrifuging, and collecting a precipitate; and S4, performing adherent purification on the cells obtained by collecting the precipitates in the step S3, and removing non-adherent cells to obtain the B lymphocytes. According to the extraction and purification method disclosed by the invention, researchers can efficiently enrich and obtain high-purity B lymphocyte populations from complex tissues under conventional laboratory conditions without purchasing professional sorting equipment, and the purity can meet strict requirements of various subsequent cell experiments and immune experiments.

This document provides compositions and methods for modulating the internalization properties of cell surface molecules, such as converting non-internalized cell surface antigens into internalized cell surface antigens and converting internalized cell surface antigens into non-internalized cell surface antigens. In some embodiments, engineered antibodies are provided, each comprising an antigen-binding moiety specific to a guide antigen and another antigen-binding moiety specific to an effector antigen, wherein the internalization properties of said engineered antibody or a functional fragment thereof are determined by the relative surface density ratio of said guide antigen to said effector antigen. Recombinant cells, recombinant nucleic acids encoding such engineered antibodies, and pharmaceutical compositions containing them are also provided. This disclosure also provides methods for modulating cell internalization in cells or subjects, and methods for modulating cell type-selective signaling in subjects and / or for treating diseases.

Disclosed is a computer-implemented method for identifying, for a subject, at least one antigen which is expected to induce a T-cell response to attack unhealthy cells in the subject. The invention further relates to using said antigens for designing personalized vaccines and to the use of such personalized vaccine and personalized vaccine compositions in kits and methods for the treatment of disease.

The present invention provides a configuration of a trispecific antigen-binding molecule, and also provides a trispecific antigen-binding molecule constructed based on this configuration against two tumor antigens GPRC5D and BCMA and a T-cell surface antigen CD3, a specific binding molecule for GPRC5D or a fragment thereof, a specific binding molecule for BCMA or a fragment thereof, a pharmaceutical composition comprising the trispecific antigen-binding molecule or the specific binding molecule or a fragment thereof, and their related applications in tumor treatment.

The present disclosure relates to multispecific antibodies that specifically bind to GPRC5D and / or BCMA tumor antigen and T cell surface antigen CD3, as well as pharmaceutical compositions comprising the same, uses and clinical therapeutic applications.

This invention relates to a sample processing reagent and its application in flow cytometry analysis, belonging to the field of flow cytometry analysis technology. The invention provides a sample processing reagent comprising a hemolysin and a cell-permeable agent. The hemolysin comprises tris(hydroxymethyl)aminomethane (Tris), sodium chloride, calcium chloride, disodium ethylenediaminetetraacetate, paraformaldehyde, and a solvent. The cell-permeable agent comprises sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, nonylphenol polyoxyethylene ether, Triton X-100, paraformaldehyde, and a solvent. The hemolysin is mild and highly effective, providing complete hemolysis and clear cell clustering. The cell-permeable agent permeates the cell membrane under isotonic and neutral conditions, minimizing damage to cell surface antigens and effectively detecting both cytoplasmic and nuclear antigens.

Disclosed are compositions of lipid nanoparticles (LNPs) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid may be conjugated to a binding moiety to form a targeted LNP (tLNP). The disclosed tLNP preferentially delivers a nucleic acid molecule or other negatively charged payload to a cell expressing a cell surface antigen recognized by the binding moiety of the tLNP and has better tolerance compared to LNP and tLNP comprising ionizable cationic lipids found in commercially available LNP-containing medicaments.

The present disclosure provides immune cells genetically modified to produce two antigen-triggered polypeptides, each recognizing a different cell surface antigen, wherein the two different cell surface antigens employed are selected from those pairs described herein. The present disclosure further provides systems comprising two antigen-triggered polypeptides (or nucleic acids encoding same), each recognizing a different cell surface antigen, wherein the two different cell surface antigens employed are selected from those pairs described herein. Also provided are method of killing a target cancer cell, using the described genetically modified immune cells and / or systems. The present disclosure also provides polyspecific-immune inducing polypeptides including first and second antigen binding domains specific for first and second antigens, respectively, present on the surface of a target cancer cell.

The present invention provides: a lipid particle which exhibits excellent effects in terms of drug efficacy manifestation, safety (low toxicity), and the like; and a production method therefor. A lipid particle provided by the present invention is, for example, a lipid particle conjugated with an antibody that specifically binds to a cell surface antigen, or an antigen-binding fragment thereof, wherein: the antibody or antigen-binding fragment thereof is covalently bonded to at least a portion of a lipid (reactive polyethylene glycol (PEG) lipid) having a reactive PEG chain contained in lipid components constituting the lipid particle; and the ratio of the reactive PEG lipid, which is not covalently bonded to the antibody or antigen-binding fragment thereof, with respect to all of the lipid components constituting the lipid particle is at most 0.1 mol%.

The application relates to the field of biological medicine, and discloses an siRNA drug delivery system, a preparation method and application thereof. The siRNA drug delivery system contains a linker formed by co-assembly of a fusion protein and an siRNA drug, the fusion protein contains a substrate peptide, an endosome fusion peptide, an antibody for targeting a cell surface antigen, and a label protein connected with the siRNA drug. The preparation method of the siRNA drug delivery system comprises the following steps: mixing the fusion protein with the siRNA drug to perform reaction I, wherein the fusion protein contains a substrate peptide, an endosome fusion peptide, an antibody for targeting a cell surface antigen, and a label protein for being connected with the siRNA drug. The system can realize the targeted delivery and site-specific release of the siRNA, can realize the high-efficiency endocytosis of nucleic acid drugs, and finally improves the treatment effect.

The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

The present disclosure relates to a multispecific antibody that specifically binds to GPRC5D and / or BCMA tumor antigens and a T cell surface antigen CD3, and a pharmaceutical composition comprising the antibody, a use of the antibody, and a clinical therapeutic application of the antibody.